Clinical trial
Mechanism of Action and Efficacy of Muraglitazar in Type 2 Diabetes
NCT00094991 · Bristol-Myers Squibb, Industry · Completed
Key facts
| NCT number | NCT00094991 |
|---|---|
| Title | Mechanism of Action and Efficacy of Muraglitazar in Type 2 Diabetes |
| Official title | Mechanism of Action and Efficacy of Muraglitazar (BMS298585) in the Treatment of Type 2 Diabetic Patients |
| Lead sponsor | Bristol-Myers Squibb, Industry |
| Collaborators | Merck Sharp & Dohme LLC Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Diabetes Mellitus, Type 2 |
| Intervention type | Drug |
| Interventions | Muraglitazar |
| Enrollment | 42 |
| Start date | May 1, 2004 |
| Primary completion | May 1, 2006 |
| Completion | May 1, 2006 |
| First posted | Nov 1, 2004 |
| Last update posted | Sep 14, 2010 |
| Countries | Italy, United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: